Rxsight, INC 10-Q quarterly reports

RxSight, Inc. reports a 14.1% revenue decrease in Q3 2025 driven by a significant drop in LDD sales, despite continued growth in Light-Adjustable Lens (LAL) implants, leading to increased operating losses and ongoing litigation.

RxSight, Inc. reported a significant increase in net loss for Q2 2025, driven by a sharp decline in Light Delivery Device (LDD) sales and rising operating expenses, despite growth in Light-Adjustable Lens (LAL) implants and improved gross margin.

RxSight's Q1 2025 revenue increased by 28.4% year-over-year, driven by strong adoption of its Light Adjustable Lens (LAL) system.

RxSight, Inc., a commercial-stage medical technology company, announced a 59% increase in revenue for Q3 2024, driven by significant adoption of its innovative Light Adjustable Lens system.

RxSight, Inc. reports a significant increase in revenue for the second quarter of 2024, fueled by strong adoption of its Light Adjustable Lens system and a growing installed base of Light Delivery Devices.

RxSight, Inc. announced a significant increase in revenue for the first quarter of 2024, primarily driven by a substantial rise in Light Adjustable Lens (LAL) sales.